Market Alert: Putin Meets Trump in Alaska: A Cold Front for Market Volatility or Calm?
Atomo Diagnostics Limited (ASX: AT1) has successfully completed the remaining $416,611.77 shortfall from its Share Purchase Plan (SPP) through a placement to institutional and sophisticated investors. The Shortfall Placement followed strong interest after the company secured a US$410,000 order from Lumos Diagnostics (ASX: LDX) for its Pascal cassettes to support growing US demand for FebriDx®. The SPP previously raised $272,387.50 via the issue of 14,723,685 shares to existing shareholders, with a further $311,000 raised through a July shortfall placement.
This final placement will see 22,519,555 shares issued at $0.0185 per share along with an equal number of options exercisable at $0.04, expiring on 14 August 2028. Settlement is expected on that date. Joint Lead Managers Bay Financial and GBA Capital advised on the transaction, with fees set at 6% of funds placed. Proceeds will fund working capital and ongoing business objectives. CEO John Kelly thanked shareholders, noting the strengthened capital position for operational progress.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Aug 14, 2025
Aug 14, 2025
Aug 14, 2025
Aug 14, 2025
Aug 14, 2025
Aug 14, 2025
Aug 14, 2025
Aug 14, 2025
Aug 14, 2025
Aug 13, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.